

(d) whether it is a fact that formulators made huge unintended profits due to such increase if so, whether notices for recovery were served if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI F. K. JAICHANDRA SINGH):

(a) and (c) To the extent information is available, the retention/pooled price for the bulk drug Doxycycline fixed/revised as per provision of Drug (Prices Control) Order, 1979 is as under:

Sl. No.	Retention/pooled price (Rs./Kg.)	Date of Notification
1	5890	24-4-1981
2	4000	20-7-1981
3	5890	2-2-1984
4	5456	2-1-1985

(b) and (d) Notices for recovery of unintended benefit into the Drugs Prices Equalisation Account have already been issued to major formulators of Doxycycline.

Recovery of unintended benefits

2600. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to state:

(a) how many cases of recovery into the Drug Prices Equalisation Account have been finalised during the period 1st January, 1987 to 31st July, 1987 as compared to the said period of last year;

(b) what are the names of the companies, bulk drugs and the amount decided against each during the said period;

(c) what prevented his Ministry to recover the amount due as an arrears of land revenue and whether any such step was taken in any case in this direction;

(d) whether any plan of action has been drawn to recover the amount due to unintended benefit made by the drug companies, if so, what are the details thereof; and

(e) what are the reasons for non-collection of amounts already finalised, delay in working the claims in favour of other companies as well as issuance of notices, in respect to number of other drugs along with the names of drugs formulations?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI F. K. JAICHANDRA SINGH):

(a) and (b) Recoveries into the DPEA have become due as a result of the Supreme Court judgement in April/May, 1987 in the case of M/s. Cyanamid (India) Ltd. and several other companies. The names of the companies and bulk drugs concerned are given in the attached Statement. (See below).

(c) to (e) As the concerned companies have failed to deposit the difference between the prices charged and those fixed by the Government within the period specified in their undertakings given to the Delhi High Court, the Government has filed petitions in the Supreme Court to issue directions to the concerned companies for depositing the difference in prices immediately.

Statement

Sl. No.	Name of the Company	Name of the Bulk Drugs/Formulations
1	2	3
1.	Geoffrey Manners and John Wyeth	Benzathine Panicilline and its formulations
2.	Pfizer Ltd	Oxytetracycline, PAS and its salts and formulations based thereon
3.	Hoechst India Ltd.	Baralgan, Pyelidine Methyl Tetracycline, Pheniramine, Glybenclamide, Frusemide and its formulations.
4.	Parke Davis	Retention price of chloramphenicol
5.	Ethnor Ltd.	Tetramesol and its formulations.
6.	Cyanamid India Ltd.	Tetracycline and formulations.
7.	Cyanamid India Ltd.	Diethyl Carbamazine formulations.
8.	Anil Starch	Dexgrose Anhydrous
9.	Merind	Dexamethasone and its formulations.
10.	Griffon Labs.	Procaine Penicillin V and formulations.
11.	Tamil Nadu Daadha	Calcium Lactate and its formulations.
12.	S.G. Pharmaceutical	Oxyphenbutazone, Oxylocaine and formulations based thereon.

Utilisation of accumulated unintended benefit

2601. SHRI RANJIT ALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 3 given in the Rajya Sabha on the 27th July 1987 and state:

(a) what is the approximate accrued unintended benefit to be recovered from the drug companies;

(b) whether it is a fact that still a number of notices relating to a large number of drugs on which unintended benefit has been made are to be issued;

(c) if so, what are the names of the drugs and the drug companies and by when all notices will be issued;

(d) whether his Ministry can use the recovered unintended benefit for any other purpose without specifying

918 RS-7.

in the announced measures; and

(e) if so, how and what are the details of other purpose for which the benefits will be used?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) to (c) The prices of about 350 bulk drugs and several thousand formulations are controlled under the DPCO, 1979. Notices have been issued to the manufacturers as and when cases of unintended benefit came to the notice of the Government. The details required in the question are quite voluminous and are not readily available. Time and efforts required for collection of these will not be commensurate with the results likely to be achieved.